Maya Balakrishnan
Overview
Explore the profile of Maya Balakrishnan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
46
Citations
845
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Shi M, Pungwe P, Comer L, Balakrishnan M, Lee T, Cholankeril G, et al.
Hepatology
. 2025 Jan;
PMID: 39874480
Background: Severe alcohol-associated hepatitis (AH) is rising in incidence with a high mortality burden. While corticosteroids are recommended for eligible patients with severe AH, no guidance exists for the timing...
2.
Peek E, Sanchez J, Weber J, Mai C, Balakrishnan M
J Grad Med Educ
. 2024 Jun;
16(3):355-356.
PMID: 38882404
No abstract available.
3.
Thrift A, Nguyen Wenker T, Godwin K, Balakrishnan M, Duong H, Loomba R, et al.
Dig Dis Sci
. 2024 May;
69(7):2430-2436.
PMID: 38700632
Background: One challenge for primary care providers caring for patients with nonalcoholic fatty liver disease is to identify those at the highest risk for clinically significant liver disease. Aim: To...
4.
Heredia N, John J, Singh S, Hwang J, Strong L, Balakrishnan M, et al.
Inquiry
. 2024 Mar;
61:469580241241272.
PMID: 38529894
Primary care physicians (PCPs) are well suited to manage patients with non-alcoholic fatty liver disease (NAFLD), but the limited, existing research suggests inadequate knowledge about the natural history, diagnostic methods,...
5.
Balakrishnan M, Rehm J
Hepatology
. 2023 Nov;
79(2):451-459.
PMID: 37943874
Chronic liver disease is a significant global health problem. Epidemiological trends do not show improvement in chronic liver disease incidence but rather a shift in etiologies, with steatotic liver disease...
6.
Zhang X, Daniel C, Soltero V, Vargas X, Jain S, Kanwal F, et al.
Am J Gastroenterol
. 2023 Sep;
119(3):505-511.
PMID: 37737674
Introduction: Diet is a modifiable metabolic dysfunction-associated steatotic liver disease (MASLD) risk factor, but few studies have been conducted among Hispanic patients, despite the fact that MASLD prevalence and severity...
7.
8.
Balakrishnan M, Liu K, Schmitt S, Heredia N, Sisson A, Montealegre J, et al.
Hepatol Commun
. 2023 Aug;
7(8).
PMID: 37534947
Background: Clinically significant weight loss-which requires sustained dietary and physical activity changes-is central to treating NAFLD. Although behavioral interventions have demonstrated effectiveness in promoting weight loss among primary prevention populations,...
9.
Cholankeril G, Kramer J, Chu J, Yu X, Balakrishnan M, Li L, et al.
J Hepatol
. 2022 Nov;
78(3):493-500.
PMID: 36402450
Background & Aims: Currently, there is no consistent information on the course of fibrosis-4 (FIB-4) score changes in non-alcoholic fatty liver disease (NAFLD) or their association with subsequent risk of...
10.
The Prevalence and Determinants of NAFLD and MAFLD and Their Severity in the VA Primary Care Setting
Thrift A, Nguyen T, Pham C, Balakrishnan M, Kanwal F, Loomba R, et al.
Clin Gastroenterol Hepatol
. 2022 Jul;
21(5):1252-1260.e5.
PMID: 35811043
Background & Aims: A recent panel of international experts proposed the disease acronym metabolic (dysfunction)-associated fatty liver disease (MAFLD) in lieu of nonalcoholic fatty liver disease (NAFLD). We aimed to...